Latest Breaking News On - Nuvation bio - Page 2 : comparemela.com

Innovent Announces Data From Pivotal Phase 2 TRUST-I Study Of Taletrectinib(ROS1 Inhibitor) Are Published In The JCO And Reported At 2024 ASCO Annual ...

SAN FRANCISCO, U.S. and SUZHOU, China, June 1, 2024 /PRNewswire/ Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceut

Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual Meeting

Nuvation Bio's (NUVB) "Outperform" Rating Reiterated at Wedbush

Wedbush restated their outperform rating on shares of Nuvation Bio (NYSE:NUVB – Free Report) in a report released on Friday, Benzinga reports. The firm currently has a $5.00 price objective on the stock. Several other equities analysts also recently weighed in on NUVB. HC Wainwright reiterated a buy rating and issued a $8.00 price objective […]

Nuvation Bio (NYSE:NUVB) Rating Reiterated by Wedbush

Wedbush reiterated their outperform rating on shares of Nuvation Bio (NYSE:NUVB – Free Report) in a report published on Friday morning, Benzinga reports. Wedbush currently has a $5.00 price objective on the stock. NUVB has been the topic of a number of other reports. Royal Bank of Canada increased their price target on shares of […]

Q2 2024 Earnings Forecast for Nuvation Bio Inc. (NYSE:NUVB) Issued By HC Wainwright

Nuvation Bio Inc. (NYSE:NUVB – Free Report) – HC Wainwright increased their Q2 2024 earnings per share estimates for shares of Nuvation Bio in a note issued to investors on Wednesday, May 22nd. HC Wainwright analyst R. Burns now anticipates that the company will earn ($0.07) per share for the quarter, up from their prior […]